Shares of Citius Pharmaceuticals (NASDAQ:CTXR) moved higher in the previous trading. Will the stock continue to move higher?
Trading Data
On Friday, CTXR stock ended flat at $1.9500 with more than 980.51K shares, compared to its average volume of 2.47 million shares. The stock has moved within a range of $1.9100 – 1.9800 after opening the trade at $1.9250.
Expands Management Team
Late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products focusing on oncology, anti-infective products, Citius Pharmaceuticals (NASDAQ:CTXR), on November 5, 2021, announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls.
Creighton will be handling global strategic regulatory and manufacturing development plans for the company’s five pipeline programs.
Myron Holubiak, Chief Executive Officer of Citius, said that the company continues to prepare the organization is on the path to success and Kelly’s achievements of 50 investigational new drug submissions as well as 20 approved market applications.
Kelly has been an advisor to the company’s team on different regulatory aspects and there is anticipation on a seamless transition to this new role. Myron also said that Kelly brings a perfect blend of strategic thinking, leadership skills as well as global regulatory expertise that would be applied to the complete clinical program for developing the company’s pipeline.
Kelly served as Vice President of Regulatory and Strategic Development at Clinipace Worldwide, a leading global contract research organization. His experience on leading teams across North America, Europe, and the Asia Pacific region overseeing submissions helped the implementation of multiple CMC development plans. These included contract manufacturing organization selection, product manufacturing, analytical development as well as product characterization.
Technical Data
CTXR stock is trading below the 20-Day and 50-Day Moving averages of $1.97 and $2.05 respectively. Moreover, the stock is trading below 200-Day moving average of $2.07. The stock is down 5% in the past month.
